Drug Profile
SMD 3117
Alternative Names: SMD-3117Latest Information Update: 22 Sep 2023
Price :
$50
*
At a glance
- Originator Sirenas Marine Discovery
- Class Antineoplastics; Auristatins; Immunotoxins
- Mechanism of Action Cell division inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 22 Sep 2023 Discontinued - Preclinical for Cancer in USA (Parenteral) (Sirenas Marine Discovery pipeline, September 2023)
- 28 Nov 2020 No recent reports of development identified for preclinical development in Cancer in USA (Parenteral)
- 20 Oct 2016 Preclinical trials in Cancer in USA (Parenteral)